Genetics >
Genetics
News, opinions and meeting coverage in genetics.
EMA Calls Halt to Reduced Dosing of Fabry Drug
Europe's equivalent of the FDA has advised that patients with Fabry disease receive the full label-recommended dosage of Genzyme's agalsidase-beta (Fabrazyme) despite the ongoing shortage of the drug, which is one of two enzyme replacement products available to treat the genetic disease.
Oct 29, 2010